The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells

Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 65; no. 5
Main Authors Tomita, Yuriko, Takeda, Makoto, Matsuyama, Shutoku
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 19.04.2021
Subjects
Letter to the Editor
COVID-19
influenza
SARS-CoV-2
T-705
Avigan
favipiravir
drug
Online AccessGet full text

Cover

More Information
Summary:Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
Citation Tomita Y, Takeda M, Matsuyama S. 2021. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells. Antimicrob Agents Chemother 65:e00020-21. https://doi.org/10.1128/AAC.00020-21.
ISSN:0066-4804
1098-6596
1098-6596
DOI:10.1128/AAC.00020-21